Synexus recruits 20% of all patients in Crestor Jupiter study
17 Apr 2008
Using just eight of its 14 hub sites Synexus recruited and randomised more than 2740 of the 15,000 patients involved in AstraZeneca's Crestor Jupiter study into cardiovascular disease.
The study, which was stopped early, due to unequivocal evidence of a reduction in cardiovascular morbidity and mortality, was carried out in 1200 sites across 26 countries.
Each Synexus site averaged more than 314 patients.
Over 90% of late stage trials are still carried out by individual primary care physicians who recruit between five and ten patients each.
The Synexus model using full-time investigators at its hub sites dramatically reduces the cost of running clinical trials through having one negotiation and contract instead of hundreds and a handful of sites to monitor.
Synexus is planning to expand into the US and further grow its network of hub sites in Eastern Europe and India.
If you would like an assessment on a clinical trial please send us your details and we will get back to you.
Have more questions? Contact us for more information
